TriangleNKTR-255 (NCT05632809)
NKTR-255 trial for Lung Cancer (NCT05632809). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally advanced non-small-cell lung cancer receiving definitive chemoradiation. Previous PD-1 or PD-L1 treatment is excluded.
The idea: NKTR-255 activates IL-15 signaling to expand natural-killer and T cells; durvalumab blocks PD-L1 immune suppression. NKTR-255 starts intravenously within three days after chemoradiation, then at three weeks. Durvalumab begins at three weeks. Both then repeat every four weeks for up to one year. Researchers assess immune-cell recovery, safety, and survival.
This phase 2 study plans 39 patients. Steven Lin leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.